Balliuzek, M., Protsenko, S., & Potiyevskaya , V. (2023). Myocarditis associated with immune checkpoint inhibitor therapies: diagnostic and treatment strategies. Voprosy Onkologii, 69(2), 219–226. https://doi.org/10.37469/0507-3758-2023-69-2-219-226

Abstract

This review aims to provide information on myocarditis and inflammatory cardiomyopathies associated with immune checkpoint inhibitor (ICI) therapies. Additionally, it will present current data on strategies for diagnosis and treatment of these conditions. As immunotherapy becomes more widely used, it has revealed diverse clinical symptoms, courses, and outcomes of cardiovascular immune-related adverse events (irAEs). These range from rare but potentially life-threatening fulminant forms to mild symptomatic courses that can lead to the development of dilated cardiomyopathy, arrhythmias, and heart failure. The review discusses the risk factors and common comorbid clinical conditions of irAE-associated myocarditis, as well as severity assessment and observation algorithms. The importance of a multidisciplinary approach to managing patients with this cardiotoxic irAE is also emphasized.

https://doi.org/10.37469/0507-3758-2023-69-2-219-226

##article.numberofdownloads## 205

##article.numberofviews## 217

pdf (Русский)

References

Caforio ALP, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 2013;34(33):2636–48. doi:10.1093/eurheartj/eht210.

Ammirati E, Frigerio M, Adler ED, et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy. Circ. Heart Fail. 2020;13(11). doi:10.1161/circheartfailure.120.007405.

Tschöpe C, Ammirati E, Bozkurt B, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat. Rev. Cardiol. 2020;18(3):169–93. doi:10.1038/s41569-020-00435-x.

Corrado D, Basso C, Thiene G. Sudden cardiac death in young people with apparently normal heart. Cardiovasc Res. 2001;50(2):399408. doi:10.1016/s0008-6363(01)00254-1.

Lota AS, Halliday B, Tayal U, et al. Epidemiological trends and outcomes of acute myocarditis in the National Health Service of England. Circulation. 2019;140:A11463.

Veronese G, Ammirati E, Brambatti M, et al. Viral genome search in myocardium of patients with fulminant myocarditis. Eur. J. Heart Fail. 2020;22(7):1277–80. doi:10.1002/ejhf.1738.

Guglin M, Ballut K, Ilonze O, et al. Clinical variants of myocardial involvement in COVID-19-positive patients: a cumulative experience of 2020. Heart Fail Rev. 2021;27(4):1341–53. doi:10.1007/s10741-021-10129-2.

Nguyen LS, Cooper LT, Kerneis M, et al. Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database. Nat. Commun. 2022;13(1). doi:10.1038/s41467-021-27631-8.

Zamorano JL, Lancellotti P, Rodriguez Muñoz DR, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur. Heart J. 2016;37(36):2768–801. doi:10.1093/eurheartj/ehw211.

Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update. J Clin Oncol. 2021;39(36):40734126. doi:10.1200/JCO.21.01440.

Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):17491755. doi:10.1056/NEJMoa1609214.

Varricchi G, Galdiero MR, Marone G, et al. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open. 2017;2(4):e000247. doi:10.1136/esmoopen-2017-000247.

Heinzerling L, Ott PA, Hodi FS, et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer. 2016;4(1). doi:10.1186/s40425-016-0152-y.

Błyszczuk P. Myocarditis in humans and in experimental animal models. Front. Cardiovasc. Med. 2019;6. doi:10.3389/fcvm.2019.00064.

Hu J-R, Florido R, Lipson EJ, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115(5):854–68. doi:10.1093/cvr/cvz026.

Проценко С.А., Антимоник Н.Ю., Баллюзек М.Ф., и др. Практические рекомендации по управлению иммуноопосредованными нежелательными явлениями. Злокачественные опухоли: Практические рекомендации. RUSSCO. 2022;12(3s2):203–241. doi:10.18027/2224-5057-2022-12-3s2-203-241 [Protsenko SA, Antimonic NYu, Ballyuzek MF, et al. Practical recommendations for the management of immune-mediated adverse events. Malignant Tumors: RUSSCO Practical Recommendations. 2022;12(3s2):203–41. doi:10.18027/2224-5057-2022-12-3s2-203-241 (In Russ.)].

Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol. 2017;70(6):776–803. doi:10.1016/j.jacc.2017.04.025.

Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229–361. doi:10.1093/eurheartj/ehac244.

Palaskas N, Lopez-Mattei J, Durand JB, et al. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020;9(2):e013757. doi:10.1161/JAHA.119.013757.

Dolladille C, Ederhy S, Allouche S, et al. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J. Immunother. Cancer. 2020;8(1):e000261. doi:10.1136/jitc-2019-000261.

Lyon AR, Yousaf N, Battisti NML, et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447e458. doi:10.1016/S1470-2045(18)30457-1.

Atallah-Yunes SA, Kadado AJ, Kaufman GP, et al. Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases. J Cancer Res Clin Oncol. 2019;145(6):15271557. doi:10.1007/s00432-019-02927-x.

Guo CW, Alexander M, Dib Y, et al. A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies. Eur J Cancer. 2020;124:1524. doi:10.1016/j.ejca.2019.09.009.

Kadota H, Gono T, Shirai Y, et al. Immune checkpoint inhibitor-induced myositis: a case report and literature review. Curr. Rheumatol. Rep. 2019;21(4). doi:10.1007/s11926-019-0811-3.

Allenbach Y, Anquetil C, Manouchehri A, et al. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun. Rev. 2020;19(8):102586. doi:10.1016/j.autrev.2020.102586.

Kociol RD, Cooper LT, Fang JC, et al. Recognition and initial management of fulminant myocarditis. Circulation. 2020;141(6). doi:10.1161/cir.0000000000000745.

Caforio ALP, Adler Y, Agostini C, et al. Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. Eur. Heart J. 2017;38(35):2649–62. doi:10.1093/eurheartj/ehx321.

Gürdoğan M. Myocarditis associated with immune check-point inhibitors: Practical considerations in diagnosis and management. Anatol. J. Cardiol. 2020; doi:10.14744/anatoljcardiol.2020.79584.

Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755–64. doi:10.1016/j.jacc.2018.02.037.

Abou R, van der Bijl P, Bax JJ, et al. Global longitudinal strain: clinical use and prognostic implications in contemporary practice. Heart. 2020;106(18):143844. doi:10.1136/heartjnl-2019-316215.

Awadalla M, Mahmood SS, Groarke JD, et al. Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. J. Am. Coll. Cardiol. 2020;75(5):467–78. doi:10.1016/j.jacc.2019.11.049.

Virizuela JA, García AM, de las Peñas R, et al. SEOM clinical guidelines on cardiovascular toxicity (2018). Clin. Transl. Oncol. 2019;21(1):94–105. doi:10.1007/s12094-018-02017-3.

Tan NYL, Anavekar NS, Wiley BM. Concomitant myopericarditis and takotsubo syndrome following immune checkpoint inhibitor therapy. BMJ Case Rep. 2020;13(9):e235265. doi:10.1136/bcr-2020-235265.

Serzan M, Rapisuwon S, Krishnan J, et al. Takotsubo cardiomyopathy associated with checkpoint inhibitor therapy. JACC CardioOncol. 2021;3(2):330–4. doi:10.1016/j.jaccao.2021.02.005.

Harries I, Liang K, Williams M, et al. Magnetic resonance imaging to detect cardiovascular effects of cancer therapy. JACC: CardioOncol. 2020;2(2):270–92. doi:10.1016/j.jaccao.2020.04.011.

Sato T, Nakamori S, Watanabe S, et al. Monitoring of the evolution of immune checkpoint inhibitor myocarditis with cardiovascular magnetic resonance. Circ. Cardiovasc. Imaging. 2020;13(11). doi:10.1161/circimaging.120.010633.

Boughdad S, Latifyan S, Fenwick C, et al. 68Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis. J. Immunother Cancer. 2021;9(10):e003594. doi:10.1136/jitc-2021-003594.

Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171–90. doi:10.1016/j.annonc.2019.10.023.

Koelzer VH, Rothschild SI, Zihler D, et al. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study. J. Immunother Cancer. 2016;4(1). doi:10.1186/s40425-016-0117-1.

Lehmann LH, Cautela J, Palaskas N, et al. Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor–associated myocarditis. JAMA Cardiol. 2021;6(11):1329. doi:10.1001/jamacardio.2021.2241.

Bonaca MP, Olenchock BA, Salem J-E, et al. Myocarditis in the Setting of Cancer Therapeutics. Circulation. 2019;140(1):80–91. doi:10.1161/circulationaha.118.034497.

Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother Cancer. 2017;5(1). doi:10.1186/s40425-017-0300-z.

Balanescu DV, Donisan T, Palaskas N, et al. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy. Cardiovasc. Pathol. 2020;47:107211. doi:10.1016/j.carpath.2020.107211.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

Vera Potiyevskaya , Альберт Ахобеков, Evgenii Khmelevsky , Elena Kononova , Radiation-induced ischemic heart disease , Voprosy onkologii : Vol. 68 No. 2 (2022)
Ekaterina Degtiareva, Svetlana Protsenko, Aglaya Iyevleva, Evgeny Imyanitov, Real-world data on the incidence of immune-related adverse events associated with anti-PD-1/PD-L1 treatment in Russia , Voprosy onkologii : Vol. 68 No. 2 (2022)
Konstantin Laktionov, Alla Arzumanyan, Larisa Bolotina, Valeriy Breder, Natalya Buevich, A. Danilova, Anna Zinkovskaya, Anna Kornietskaya, M. Kramchaninov, Ye. Kushniruk, Dilorom Latipova, Fedor Moiseenko, Tatyana Nikitina, Mariya Okruzhnova, Sergey Orlov, Rashida Orlova, N. Porfireva, Svetlana Protsenko, Kseniya Sarantseva, Daniil Stroyakovskiy, Yelena Filippova, Tatyana Ionova, EFFICACY OF NIVOLUMAB (NWO) DURING 2+ LINE TREATMENT AND QUALITY OF LIFE IN PATIENTS WITH ADVANCED REFRACTORY NON-SMALL CELL LUNG CANCER: INTERIM RESULTS OF PROSPECTIVE OBSERVATIONAL STUDY , Voprosy onkologii : Vol. 65 No. 1 (2019)
Evgeny Imyanitov, Svetlana Protsenko, Tatiana Semiglazova, Opportunities for antitumor drugs replacement , Voprosy onkologii : Vol. 68 No. 6 (2022)
Tatyana Semiglazova, Natalya Buevich, Yekaterina Anokhina, Yevgeniya Kharchenko, Mikhail Osipov, Veronika Klimenko, Margarita Motalkina, Yuriy Komarov, Gulfiya Teletaeva, Dilorom Latipova, Sergey Alekseev, Larisa Filatova, Aleksey Novik, Anna Semenova, Irina Baldueva, Aleksandr Stukov, Svetlana Protsenko, Z. Kotova, HOW APPROACHES TO DRUG THERAPY FOR MALIGNANT TUMORS HAVE CHANGED (TO THE FIRST DOMESTIC ANTITUMOR DRUG IS DEDICATED) , Voprosy onkologii : Vol. 63 No. 2 (2017)
A. Oganesian, Svetlana Protsenko, Irina Baldueva, Anna Semenova, Yekaterina Anokhina, Aleksey Novik, EVALUATION OF THE EFFECTIVENESS OF MODERN IMMUNOTHERAPY , Voprosy onkologii : Vol. 66 No. 3 (2020)
Елена Ульрих, Gulfiya Teletaeva, Anna Semenova, Evgenii Levchenko, Dariya Ulrikh, Igor Berlev, Tatyana Semiglazova, Svetlana Protsenko, Adel Urmancheeva, Individualization in the treatment of resistant forms of gestational trophoblastic neoplasia , Voprosy onkologii : Vol. 66 No. 6 (2020)
Yekaterina Anokhina, V. Rubinchik, Yekaterina Yaremenko, Gulfiya Teletaeva, Dilorom Latipova, Anna Semenova, Tatyana Semiglazova, Irina Baldueva, Svetlana Protsenko, Aleksey Novik, A. Oganesyan, IPILIMUMAB IN PATIENTS WITH DISSEMINATED MELANOMA: THE N.N. PETROV NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY EXPANDED ACCESS PROGRAM EXPERIENCE , Voprosy onkologii : Vol. 64 No. 3 (2018)
Irina Baldueva, N. Avdokina, Aleksey Belyaev, Aleksandr Shcherbakov, Tatyana Semiglazova, Yekaterina Anokhina, Yuriy Komarov, Dilorom Latipova, Gulfiya Teletaeva, Anna Semenova, Olga Galiullina, Natalya Yemelyanova, Nino Pipia, Mark Gelfond, Svetlana Protsenko, Anna Danilova, Tatyana Nekhaeva, Aleksey Novik, Z. Kotova, PERSPECTIVES IN ACTIVE SPECIFIC IMMUNOTHERAPY WITH AUTOLOGOUS IMMATURE DENDRITIC CELLS COMBINED WITH PHOTODYNAMIC THERAPY AND CYCLOPHOSPHAMIDE IN PATIENTS WITH DISSEMINATED MELANOMA RESISTANT TO STANDARD THERAPY , Voprosy onkologii : Vol. 63 No. 2 (2017)
Marina Balliuzek, Svetlana Protsenko, Sergey, Maria, Dzerasa, Combined immune-mediated adverse events in treatment with immune checkpoint inhibitors , Voprosy onkologii : Vol. 68 No. 6 (2022)

1 2 > >>